Search Results for 'Rbv-Hcv'

Rbv-Hcv published presentations and documents on DocSlides.

C-WORTHY Study Part D: grazoprevir + elbasvir + RBV in genotype 3
C-WORTHY Study Part D: grazoprevir + elbasvir + RBV in genotype 3
by UnicornLove
C-WORTHY/D. GZR + EBR + RBV. GZR + EBR + RBV. N =...
SOF + RBV
SOF + RBV
by debby-jeon
SOF + RBV. Randomisation*. 1 : 1 : 1. Open-label....
SOF + EBR + GZR + RBV
SOF + EBR + GZR + RBV
by test
N = 12. N = 13. W24. W16. SOF + EBR + GZR + RBV. ...
MK3 MK3  + RBV
MK3 MK3 + RBV
by min-jolicoeur
Randomisation. Open-label. W8. * Liver biopsy or ...
Pharmacometrics and Biostatistics Interactions at the FDA
Pharmacometrics and Biostatistics Interactions at the FDA
by byrne
Jeffry Florian, Ph.D.. Division of Pharmacometrics...
Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology
Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology
by badra
Duke University School of Medicine. Durham, North ...
522432468WPbVZOeORbVcPSUZbVSTZZeWUTbVaTbVSgcbeeWbVaSWRbVObVbbVgTTWRc
522432468WPbVZOeORbVcPSUZbVSTZZeWUTbVaTbVSgcbeeWbVaSWRbVObVbbVgTTWRc
by daisy
B7AB8DW10--62712/0216U28411204- f-25189455DVReWbVT...
Open-label
Open-label
by pamella-moone
* Liver biopsy or . Fibroscan. ≤. 12.5 . kPa....
COSMOS
COSMOS
by sherrill-nordquist
SOF + SMV + RBV. SOF + SMV. Randomisation. 2 : 1 ...
Forns
Forns
by ellena-manuel
X. J . Hepatology. 2015; 63: 564-72. C-SALVAGE ...
SOF/VEL + RBV
SOF/VEL + RBV
by celsa-spraggs
N = 69. >. 18 years. Failure to SOF/VEL . or ...
SMV 12W + PEG-IFN + RBV 24-48W **
SMV 12W + PEG-IFN + RBV 24-48W **
by alexa-scheidler
SMV 24W + PEG-IFN + RBV 24-48W **. Randomisation ...
Elbasvir
Elbasvir
by calandra-battersby
+ . Grazoprevir. +/- Ribavirin in . Treatment-N...
Ombitasvir-
Ombitasvir-
by kittie-lecroy
Paritaprevir. -. Ritonavir. . and . Dasabuvir. ...
C-WORTHY Study Part
C-WORTHY Study Part
by karlyn-bohler
D : . grazoprevir. . + . elbasvir. + RBV in ge...
Randomisation
Randomisation
by pamella-moone
*. 1:1. Open-label. ≥ 18 years. HCV genotype ...
Reddy KR. Lancet Infect Dis. 2015;15:27-35
Reddy KR. Lancet Infect Dis. 2015;15:27-35
by natalia-silvester
ATTAIN. SMV + TVR placebo. + PEG-IFN + RBV. TVR ...
Design
Design
by test
PTV150/r + OBV + . DSV . + RBV. PTV150/r + . DSV...
Étude PEARL III : ABT-450/r/267 + ABT-333 ± RBV
Étude PEARL III : ABT-450/r/267 + ABT-333 ± RBV
by tatiana-dople
dans les génotypes 1b naïfs de traitement . (1)...
3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in
3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in
by yoshiko-marsland
TURQUOISE-II. Phase 3. . Treatment. Naïve and ...
David Fletcher, MD
David Fletcher, MD
by tatiana-dople
Department of Medicine. University of Toronto. Co...
GZR + EBR
GZR + EBR
by celsa-spraggs
C-WORTHY Study Part C: . grazoprevir. . + . elba...
Ledipasvir-Sofosbuvir + RBV in Decompensated Cirrhosis or Post-Liver Transplantation
Ledipasvir-Sofosbuvir + RBV in Decompensated Cirrhosis or Post-Liver Transplantation
by ahmir653
SOLAR-2. Source: . Manns. M, et al. Lancet Infect...
Rare barometer survey  The journey to diagnosis for people living with a rare disease
Rare barometer survey The journey to diagnosis for people living with a rare disease
by anya
Goals of the diagnosis survey. Measuring the . tim...
Clinical Group
Clinical Group
by summer
CC By 010 Therapeutic Challenges College of Pharma...
SOF/VEL 400/100 mg  qd N = 75
SOF/VEL 400/100 mg qd N = 75
by danika-pritchard
W24. SOF/VEL. >. 18 years. Chronic HCV infect...
HIV Pipeline Cabotegravir-LA
HIV Pipeline Cabotegravir-LA
by liane-varnes
(GSK-744; CAB). For . PrEP. INI. ViiV. Topical mi...
HIV Pipeline Doravirine 2
HIV Pipeline Doravirine 2
by giovanna-bartolotta
(MK-1439; DOR). . NNRTI. Merck. Filed with USFDA...
The Resource Based View of the Firm (RBV)
The Resource Based View of the Firm (RBV)
by alida-meadow
B290. The object of strategic analysis…. Explai...
Not  randomised Open-label
Not randomised Open-label
by cheryl-pisano
18-70 years. HCV genotype 1 or 3. Naïve or failu...
Sofosbuvir, Ribavirin, GS
Sofosbuvir, Ribavirin, GS
by min-jolicoeur
-. 0938 in GT 1-4. QUANTUM. Phase . 2b. Treatment...
ALLY-1
ALLY-1
by stefany-barnette
Design. Objective. SVR. 12. (HCV RNA < 25 IU/...
MK3 + RBV
MK3 + RBV
by jane-oiler
N = 45. N = 49. W24. W16. MK3. > . 18 years. H...
No  randomisation
No randomisation
by tatiana-dople
N = 100. W12. W24. Arm B: . compensated cirrhosis...
Ombitasvir-Paritaprevir-Ritonavir
Ombitasvir-Paritaprevir-Ritonavir
by sherrill-nordquist
. and Dasabuvir +/- . RBV in . GT1b. PEARL-II. P...
OBV/PTV/r
OBV/PTV/r
by kittie-lecroy
+ DSV + RBV. No randomisation. Open-label. TOPAZ-...
3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in
3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in
by conchita-marotz
SAPPHIRE-I. Phase 3. . Treatment. . Naïve. Fel...
Sofosbuvir
Sofosbuvir
by conchita-marotz
ELECTRON (Overview): 6 parts, 22 arms. Phase . 2....
The Resource Based View of the Firm (RBV)
The Resource Based View of the Firm (RBV)
by celsa-spraggs
B290. The object of strategic analysis…. Explai...